AR041885A1 - SULFONAMIDE COMPOSITE, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE TO PREPARE SUCH COMPOSITION - Google Patents

SULFONAMIDE COMPOSITE, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE TO PREPARE SUCH COMPOSITION

Info

Publication number
AR041885A1
AR041885A1 ARP030104038A ARP030104038A AR041885A1 AR 041885 A1 AR041885 A1 AR 041885A1 AR P030104038 A ARP030104038 A AR P030104038A AR P030104038 A ARP030104038 A AR P030104038A AR 041885 A1 AR041885 A1 AR 041885A1
Authority
AR
Argentina
Prior art keywords
alkyl
hydrogen
composition
pharmaceutical composition
sulfonamide
Prior art date
Application number
ARP030104038A
Other languages
Spanish (es)
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of AR041885A1 publication Critical patent/AR041885A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un compuesto de sulfonamida que tiene la fórmula (1), en la cual: Ar es fenilo sustituido o sin sustituir con uno o dos de los siguientes: halógenos, CN, S(alquilo C1-6), CF3, OCF3, SCF3, alquilo C1-6, alcoxi C1-6, CO2(alquilo C1-6) o NO2; Y es O o S; Z es hidrógeno, halógeno o alquilo C1-6; R2 es hidrógeno, halógeno, CN o alquilo C1-4; R1 es hidrógeno o alquilo C1-6; o una sal farmacéuticamente aceptable del mismo. Composición farmacéutica que comprende un compuesto de fórmula (1) y un vehículo o excipiente farmacéuticamente aceptable. La presente se refiere a sulfonamidas, composiciones farmacéuticas que las contienen y su uso para tratar estados asociados con un desequilibrio de urotensina-II antagonizando el receptor de uretensina-II. Dichos estados pueden ser fallo cardiaco congestivo, apoplejía, enfermedad cardiaca isquémica, angina, isquemia de miocardio, arritmia cardiaca, hipertensión esencial y pulmonar, enfermedad renal, fallo renal agudo y crónico, entre otros.A sulfonamide compound having the formula (1), in which: Ar is substituted or unsubstituted phenyl with one or two of the following: halogens, CN, S (C1-6 alkyl), CF3, OCF3, SCF3, alkyl C1-6, C1-6 alkoxy, CO2 (C1-6 alkyl) or NO2; Y is O or S; Z is hydrogen, halogen or C1-6 alkyl; R2 is hydrogen, halogen, CN or C1-4 alkyl; R1 is hydrogen or C1-6 alkyl; or a pharmaceutically acceptable salt thereof. Pharmaceutical composition comprising a compound of formula (1) and a pharmaceutically acceptable carrier or excipient. This refers to sulfonamides, pharmaceutical compositions containing them and their use to treat conditions associated with an imbalance of urotensin-II by antagonizing the uretensin-II receptor. These conditions can be congestive heart failure, stroke, ischemic heart disease, angina, myocardial ischemia, cardiac arrhythmia, essential and pulmonary hypertension, kidney disease, acute and chronic renal failure, among others.

ARP030104038A 2002-11-06 2003-11-04 SULFONAMIDE COMPOSITE, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE TO PREPARE SUCH COMPOSITION AR041885A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42416202P 2002-11-06 2002-11-06

Publications (1)

Publication Number Publication Date
AR041885A1 true AR041885A1 (en) 2005-06-01

Family

ID=32312762

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030104038A AR041885A1 (en) 2002-11-06 2003-11-04 SULFONAMIDE COMPOSITE, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE TO PREPARE SUCH COMPOSITION

Country Status (4)

Country Link
AR (1) AR041885A1 (en)
AU (2) AU2003287529A1 (en)
TW (1) TW200418831A (en)
WO (2) WO2004043948A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0414777A (en) 2003-09-26 2006-11-21 Actelion Pharmaceuticals Ltd compounds, pharmaceutical compositions, use of one or more compounds, and method of treating a patient suffering from a disorder
AU2005293196B2 (en) 2004-10-12 2012-03-22 Actelion Pharmaceuticals Ltd 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea as crystalline sulfate salt
CL2007002097A1 (en) 2006-07-20 2008-01-18 Smithkline Beecham Corp Compounds derived from pyrrolidine or morpholine antagonists of urotensin ii; pharmaceutical composition comprising said compounds; and its use to treat congestive heart failure, ischemic heart failure, angina, myocardial ischemia, overactive bladder, asthma and / or copd, among others.
US9096558B2 (en) 2010-07-09 2015-08-04 Pfizer Limited N-sulfonylbenzamide compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3378565A (en) * 1966-04-25 1968-04-16 Dow Chemical Co Sulfamoylpyridyl phosphorothioates and intermediates therefor
US5338739A (en) * 1994-03-10 1994-08-16 Hoechst-Roussel Pharmaceuticals Inc. (Pyrrolidinyl)phenyl carbamates, compositions and use
US5869428A (en) * 1995-03-13 1999-02-09 Ishihara Sangyo Kaisha Ltd. Pyridonesulfonylurea compounds, process for their production and herbicides containing them

Also Published As

Publication number Publication date
WO2004043463A3 (en) 2004-06-17
WO2004043463A2 (en) 2004-05-27
WO2004043948A1 (en) 2004-05-27
TW200418831A (en) 2004-10-01
AU2003287529A1 (en) 2004-06-03
AU2003291264A1 (en) 2004-06-03

Similar Documents

Publication Publication Date Title
CY1106959T1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING VALSARTAN AND NEP INHIBITORS
EA200101232A1 (en) PHENOXYPROPYLAMINE COMPOUNDS
PE20140630A1 (en) BRANCHED 3-PHENYLPROPIONIC ACID DERIVATIVES AND THEIR USE
RU2448976C2 (en) Hcv/hiv inhibitors and their application
AR052866A1 (en) SUBSTITUTED MONOCICLIC PHENYL-METANONES
CL2008001205A1 (en) Compounds derived from bicyclo [2.2.2] octene; pharmaceutical composition that contains them; and use in the treatment or prevention of stable chronic angina, hypertension, renal and cardiac ischemia, cardiac arrhythmias, cardiac hypertrophy and congestive heart failure.
AR109958A1 (en) BICYCLIC LACTAMAS OF PIRIDONA AND ITS METHODS OF USE
AR042109A1 (en) MANDELIC ACID DERIVATIVES, PREPARATION PROCEDURE, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, AND, USES
RU2283835C3 (en) HETEROCYCLIC DERIVATIVES AND DRUGS
EA200201179A1 (en) DERIVATIVES 2-AMINOKARBONIL-9H-PURINA
AR068054A1 (en) PIRROLOPIRIMIDINE COMPOUNDS
PE20061155A1 (en) INDOLINONE DERIVATIVES AS AGENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES
AR071385A1 (en) COMPOUNDS OF 2-IMINO-3-METHYL PIRROLOPIRIMIDINONE REPLACED WITH THIOPHENYLL, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND USE OF THE SAME FOR THE TREATMENT OF PATHOLOGIES ASSOCIATED WITH THE BETA AMYLOID PROTEIN, SUCH AS ALZHEIMAS DE OMOSTER DE OMOS.
EA200300453A1 (en) 3-AROYLINDOL DERIVATIVES AND THEIR APPLICATION AS AGONISTS OF CB2 RECEPTORS
AR035430A1 (en) INDANIL ACILATED AMINAS, A METHOD FOR THEIR SYNTHESIS, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT
PE20070218A1 (en) AMINO-HYDANTOIN CYCLOALKYL COMPOUNDS AND USE OF THESE FOR THE MODULATION OF ß-SECRETASE
CO5640098A2 (en) BIARILOXIMETILAREN-CARBOXILIC ACIDS
EA200400815A1 (en) CONTROLLED SYNTHESIS OF ZIPRAZIDONA AND ITS COMPOSITIONS
AR066669A1 (en) IMIDAZOLONA DERIVATIVES AS INHIBITORS OF BENCIMIDAZOLONA QUIMASA. PHARMACEUTICAL COMPOSITIONS.
AR073031A1 (en) THERAPEUTIC COMPOSITIONS THAT CONTAIN MACITENT
PE20061451A1 (en) DIARYLSULFONE SULFONAMIDES DERIVED COMPOUNDS
AR048213A1 (en) 1- (4-MONO-Y DI-HALOMETILSULFONILFENIL) -2-ACILAMINO-FLUORPROPANOLES ANALOGS TO FLORFENICOL
CO6220853A2 (en) DERIVATIVES OF PENTAFLUOROTIOBENZAMIDO ACETONITRILO AS ANTIPARASITARY AGENTS
EA200200912A1 (en) NEW INDOLIN-2-ONE DERIVATIVES, THEIR RECEIVING AND THEIR APPLICATION AS LIGANDS OF OXYTOCIN RECEPTORS
CL2007002097A1 (en) Compounds derived from pyrrolidine or morpholine antagonists of urotensin ii; pharmaceutical composition comprising said compounds; and its use to treat congestive heart failure, ischemic heart failure, angina, myocardial ischemia, overactive bladder, asthma and / or copd, among others.

Legal Events

Date Code Title Description
FB Suspension of granting procedure